Kymera holds immunology R&D day; discloses new targets and clinical timelines

Kymera Therapeutics, Inc.

Company held virtual immunology R&D day on Jan 4, 2024, highlighting emerging pipeline.
New target disclosures and supporting preclinical data presented.
Clinical study initiation timing provided for immunology programs.
No financial data or earnings guidance included in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.